Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.23 USD +9.31% Intraday chart for Lyell Immunopharma, Inc. +9.31% +14.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -2- DJ
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000 MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc. CI
MaxCyte's strategic platform licences redeem otherwise modest results AN
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from S&P Biotechnology Select Industry Index CI
HC Wainwright Trims Lyell Immunopharma's Price Target to $8 From $9, Maintains Buy Rating MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $25,000 MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress CI
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform CI
North American Morning Briefing : Investors Look -2- DJ
JPMorgan Downgrades Lyell Immunopharma to Neutral From Overweight, Adjusts Price Target to $5 From $15 MT
Insider Sell: Lyell Immunopharma MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q2 Revenue $27,000 MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
MaxCyte Signs Strategic Platform License with Lyell Immunopharma MT
MaxCyte inks strategic platform license with Lyell Immunopharma AN
Lyell Immunopharma Names Chief Business Officer MT
Lyell Immunopharma, Inc. Appoints Matthew Lang as Chief Business Officer CI
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell 3000E Index CI
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell Microcap Index CI
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell Microcap Value Index CI
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell 3000E Value Index CI
Chart Lyell Immunopharma, Inc.
More charts
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.23 USD
Average target price
6 USD
Spread / Average Target
+169.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Lyell Immunopharma, Inc. - Nasdaq
  4. News Lyell Immunopharma, Inc.
  5. Lyell Immunopharma Q3 Non-GAAP Net Loss Widens, Revenue Rises